
Day Return
YTD Return
1-Year Return
3-Year Return
5-Year Return
Note: Sector performance is calculated based on the previous closing price of all sector constituents
Industries in This Sector
Select an Industry for a Visual Breakdown
| Industry | Market Weight | YTD Return | |
|---|---|---|---|
| All Industries | 100.00% | 4.88% | |
| Drug Manufacturers - General | 42.79% | 18.82% | |
| Biotechnology | 12.17% | 0.52% | |
| Medical Devices | 11.25% | -2.55% | |
| Diagnostics & Research | 9.52% | -7.63% | |
| Healthcare Plans | 7.58% | -7.59% | |
| Medical Instruments & Supplies | 6.51% | -5.93% | |
| Medical Distribution | 3.25% | 9.31% | |
| Medical Care Facilities | 3.24% | 11.97% | |
| Drug Manufacturers - Specialty & Generic | 2.60% | 2.92% | |
| Health Information Services | 1.08% | -41.48% | |
| Pharmaceutical Retailers | 0.00% | -15.91% | |
Note: Percentage % data on heatmap indicates Day Return
All Industries
--
<= -3
-2
-1
0
1
2
>= 3
Largest Companies in This Sector
View MoreName | Last Price | 1Y Target Est. | Market Weight | Market Cap | Day Change % | YTD Return | Avg. Analyst Rating |
|---|---|---|---|---|---|---|---|
| 1,040.00 | 1,201.63 | 12.93% | 932.315B | +0.33% | -3.23% | Buy | |
| 243.45 | 231.25 | 8.13% | 586.69B | -0.45% | +17.64% | Buy | |
| 231.50 | 245.33 | 5.67% | 409.15B | +1.76% | +1.32% | Buy | |
| 121.41 | 124.89 | 4.20% | 303.256B | +1.82% | +15.34% | Buy | |
| 293.19 | 364.62 | 3.68% | 265.583B | +3.10% | -11.18% | Buy | |
| 369.19 | 345.56 | 2.76% | 198.993B | +0.82% | +12.80% | Buy | |
| 112.68 | 133.39 | 2.72% | 196.115B | +1.09% | -10.06% | Buy | |
| 154.98 | 153.08 | 2.67% | 192.281B | +2.09% | +26.27% | Buy | |
| 504.82 | 666.46 | 2.63% | 189.665B | -0.98% | -12.88% | Buy | |
| 485.84 | 611.82 | 2.39% | 172.536B | +1.51% | -14.22% | Buy |
Investing in the Healthcare Sector
Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds
ETF Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
|---|---|---|---|---|
| 157.67 | 40.98B | 0.08% | +1.85% | |
| 290.39 | 19.812B | 0.09% | +0.88% | |
| 172.55 | 8.534B | 0.44% | +2.24% | |
| 122.86 | 8.336B | 0.35% | +0.76% | |
| 100.95 | 4.621B | 0.40% | +3.64% |
Mutual Fund Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
|---|---|---|---|---|
| 207.90 | 39.263B | 0.32% | +1.63% | |
| 87.66 | 39.263B | 0.32% | +1.63% | |
| 145.29 | 19.812B | 0.09% | +0.94% | |
| 11.18 | 15.226B | 0.00% | +0.66% | |
| 134.20 | 15.226B | 0.00% | +0.74% |
Healthcare Research
View MoreDiscover the Latest Analyst and Technical Research for This Sector
Analyst Report: ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
RatingPrice TargetAnalyst Report: IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
RatingPrice TargetAnalyst Report: ICU Medical, Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
RatingPrice TargetAnalyst Report: Bio-Techne Corporation
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
RatingPrice Target

















